Precision wellness with GLP-1 and tirzepatide therapy means understanding how your individual metabolism, kidney function, and genetic predispositions influence supplement tolerance
Phase 3 trial data has now demonstrated weight loss outcomes that, in some patient groups, approach those previously only achieved through bariatric surgery
The meds may also decrease the risk of drug and alcohol use disorders
Lillys triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
Often, you can help with: Recovery support Inflammation management Skin quality Body composition General wellness Work with your medical director to list approved, evidence-based options so your staff can discuss them confidently
GLP-1 Is Going the Way of Gut Health Supplements that are labeled as GLP-1 boosters are everywhere